Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens

DW Kwok, NO Stevers, T Nejo, LH Chen, I Etxeberria… - BioRxiv, 2023 - biorxiv.org
T-cell-mediated immunotherapies are limited by the extent to which cancer-specific antigens
are homogenously expressed throughout a tumor. We reasoned that recurrent splicing …

[HTML][HTML] A genomic enhancer signature associates with hepatocellular carcinoma prognosis

AJ Jeon, CG Anene-Nzelu, YY Teo, SL Chong, K Sekar… - JHEP Reports, 2023 - Elsevier
Abstract Background & Aims Lifestyle and environmental-related exposures are important
risk factors for hepatocellular carcinoma (HCC), suggesting that epigenetic dysregulation …

Multi-region spatial transcriptome analysis reveals cellular networks and pathways associated with hepatocellular carcinoma recurrence

A Aiderus, PV Seshachalam, K Idzham, M Caldez… - bioRxiv, 2023 - biorxiv.org
Hepatocellular carcinomas (HCC) are driven by various etiologies and molecular diversity at
presentation. Patient prognosis post-surgery is generally dismal, and the majority respond …

Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens

H Okada, D Kwok, N Stevers, T Nejo, L Chen… - 2023 - researchsquare.com
T-cell-based immunotherapies hold promise in treating cancer by leveraging the immune
system's recognition of cancer-specific antigens. 1 However, their efficacy is often limited in …